Sarepta price target raised to $202 from $152 at Baird

Baird analyst Brian Skorney raised the firm’s price target on Sarepta to $202 from $152 and keeps an Outperform rating on the shares. The analyst said we are raising our price target after Sarepta announced today that the FDA is electing not to call an AdCom for SRP-9001, with regulators noting that they saw no significant safety concerns in the BLA, indicating a derisking into the approval decision, in our view.